Infection of the meninges surrounding the brain and spinal cord (meningitis), or of the brain (encephalitis) can have high mortality and morbidity rates depending on the source of infection. Acute ...
The US Food and Drug Administration (FDA) today approved the first nucleic acid-based test of cerebrospinal fluid (CSF) that can simultaneously detect 14 pathogens responsible for central nervous ...
BioMérieux's BioFire Diagnostics got an FDA OK for its rapid meningitis and encephalitis test, a feather in the company's cap as it diversifies its portfolio and ramps up business in an increasingly ...
SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...
MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
US FDA grants BioFire Diagnostics to market CSF nucleic acid-based test to detect multiple pathogens
The US Food and Drug Administration (FDA) allowed Salt Lake City, Utah-based BioFire Diagnostics to market the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of ...
BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...
SALT LAKE CITY, Utah (March 26, 2013) — BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next ...
SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, LLC, bioMérieux’s molecular biology affiliate, announced today that it has commenced clinical and analytical studies to evaluate the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results